Dexcom (DXCM) Operating Leases (2019 - 2026)

Dexcom (DXCM) has 8 years of Operating Leases data on file, last reported at $69.0 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 15.58% year-over-year to $69.0 million in Q1 2026; TTM through Mar 2026 was $69.0 million, a 15.58% increase from a year earlier, with the FY2025 full-year figure at $73.4 million, up 12.92% from the prior year.
• Operating Leases for Q1 2026 stood at $69.0 million, down from $73.4 million in the prior quarter.
• Over the last five years, Operating Leases for DXCM reached as high as $94.6 million in Q4 2022 and fell as low as $50.6 million in Q3 2025.
• Historically, Operating Leases has averaged $76.1 million across 5 years, with a median of $76.8 million in 2024.
• Across the five-year window, Operating Leases dropped 28.83% in 2025 and gained 15.58% in 2026, its largest moves.
• Year by year, Operating Leases stood at $94.6 million in 2022, then fell by 15.33% to $80.1 million in 2023, then slipped by 18.85% to $65.0 million in 2024, then grew by 12.92% to $73.4 million in 2025, then dropped by 5.99% to $69.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $69.0 million in Q1 2026, $73.4 million in Q4 2025, and $50.6 million in Q3 2025.